Report
Alex Morozov
EUR 101.80 For Business Accounts Only

In-Line 3Q for Varian; Maintaining Our Valuation

Varian Medical Systems' third-quarter results were in line with our estimates. We retain our wide moat rating and our $98 fair value estimate; after rallying notably year to date, shares now trade near our valuation. 
Oncology order growth was strong in the quarter, with total orders up 5% in constant currency. The Americas (3% gross order growth) saw good momentum in software and services in the U.S., partly offset by weak demand in Latin America. Europe, the Middle East, and Africa performed i...
Underlying
VARIAN MEDICAL SYSTEMS INC

Varian Medical Systems is a manufacturer of medical devices and software for treating cancer and other medical conditions. The company's segments are: Oncology Systems, which designs, manufactures, sells and services hardware and software products for treating cancer with radiotherapy, and treatments such as fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy and brachytherapy, as well as associated equipment; and Proton Solutions, which develops, designs, manufactures, sells and services products and systems for delivering proton therapy, for the treatment of cancer.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Alex Morozov

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch